REGN Stock Sinks As Regeneron’s Eylea Sales Suffer| Investor’s Business Daily The post REGN Stock Sinks As Regeneron’s Eylea Sales Suffer| Investor’s Business Daily appeared on BitcoinEthereumNews.com. Biotech giant Regeneron Pharmaceuticals (REGN) said Monday that sales of its linchpin Eylea drug in the final quarter of 2022 were hurt by a shift to an off-label competitor. REGN… Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Filed under: News - @ January 10, 2023 2:32 am